The Crisis of Essential Medication Withdrawals

Published: 01 July 2026. The English Chronicle Desk. The English Chronicle Online.

A truly vital medication that is currently heavily subsidised for many Australians living with opioid dependency will soon be pulled from the market entirely by the end of this year. This sudden announcement has naturally caused significant alarm among dedicated doctors and pharmacists who rely on the treatment daily. The United States pharmaceutical company known as Indivior recently confirmed that all marketing and sales of their long-acting injectable prescription opioid, which is called Sublocade, will officially cease from the thirty-first of December. A spokesperson for the company described this difficult move as a purely commercial decision made after reviewing their ongoing operations. This concerning news comes less than a single month after the pharmaceutical giant AstraZeneca announced that they would also remove their breast cancer and endometriosis medicine, known as Zoladex, from the national pharmaceutical benefits scheme and the private market. Similar to the recent decision regarding Sublocade, the company cited a distinct lack of commercial viability as the primary driver for their exit from the Australian market. The federal health minister, Mark Butler, stated just last month that global drug pricing remains in an enormous state of flux due to significant recent changes in international policy. The spokesperson for Indivior told reporters that the company intends to work closely with the appropriate Australian authorities and various medical experts to ensure that an orderly transition takes place, which should hopefully minimise disruption for those who currently depend on this specific medication for their ongoing recovery and well-being.

Sublocade was originally added to the federal pharmaceutical benefits scheme back in 2020 and was widely considered a significant and welcome advance in medical treatment for people living with opioid dependency issues. Traditional treatments such as methadone and buprenorphine often require patients to make daily or very frequent visits to a local pharmacy, which can prove to be an enormous logistical burden for many individuals. Sublocade is a highly effective, long-acting, monthly injection that is carefully administered at a local pharmacy or a GP clinic. While there is currently an alternative monthly injection called Buvidal that remains available through the government scheme, Melbourne general practitioner Dr Owen Harris noted that, in his extensive professional experience and in the experience of many other clinical colleagues, the Sublocade product is simply much better suited for some specific individuals. He explained that it is far more stable, it lasts for a longer period of time, people generally feel much better while taking it, and it has truly been a life-changing development for many of his patients. Some people can even stretch their prescribed dose out to once every six weeks, or occasionally even longer depending on their specific biological response. He stated quite honestly that it has been a life-saving and life-changing tool for many of the vulnerable patients he treats in his busy clinic. A federal health department spokesperson noted that any proposed discontinuation of a necessary medicine can cause genuine concern for patients and the clinicians who care for them. Maintaining consistent access to safe, effective, and affordable medicines remains a top priority for the department during these difficult times. The spokesperson also reiterated that these are strictly commercial decisions made by private global companies, and the Australian government cannot legally compel a company to continue supplying a specific medication if they choose to withdraw it.

Minister Butler explained last month that certain policies, such as the United States’ most favoured nations approach, are currently reshaping how major global companies think about their pricing structures across different international markets. Part of the core argument for this policy is that the United States should pay the same price as various reference countries, with figures like Donald Trump arguing that pharmaceutical companies have historically been discounting drugs to enter foreign markets such as Australia, while simultaneously subsidising those cheaper medicines by charging significantly more to patients within the United States. Critics of this specific US policy argue that pharmaceutical companies will likely not compromise their massive profits in the United States and will instead choose to raise their prices in smaller markets so the United States has to pay the same rate, or they will simply pull out of those smaller markets altogether if higher prices are not agreed upon by the local governments. An adjunct professor at the University of Sydney’s pharmacy school, Brendan Shaw, said that pharmaceutical companies are increasingly examining the financial impact on their global markets whenever they agree to supply cheaper medicines to Australia under the current government scheme. He stated that what the United States’ position has done is effectively draw these complex debates out into the light, and companies are now scrambling to adjust their strategies. It has, quite frankly, caused chaos across the industry and the broader health sector worldwide as these major companies all try to readjust to this shifting landscape. Shaw is also a former chief executive of Medicines Australia, which represents the research-based pharmaceutical industry in the country. He said he suspected that more drugs might eventually be pulled from the Australian market because of the intense financial pressures that are currently building internationally. He believes that companies are going to have to make a very difficult decision about where they put their medicines and what price levels they set, all while keeping one eye on what potential impact that might have on some of the major markets internationally.

Dependence on various opioids such as codeine, oxycodone, and heroin is deeply associated with a wide range of negative health and social harms, with medications like Buvidal and Sublocade playing a vital role in helping people to manage the ongoing effects of their dependency. On a snapshot day in 2025, there were over fifty-seven thousand Australians receiving some form of pharmacotherapy treatment for their opioid dependence, according to the latest data released by the Australian Institute of Health and Welfare. Back in 2020, pharmacist Angelo Pricolo became the first person in Australia to successfully administer a dose of Buvidal to a patient. He described both Buvidal and Sublocade, which both contain the active ingredient buprenorphine, as particularly important for those living in remote or rural areas where access to healthcare services can be quite limited. He noted that there are significant differences between Sublocade and Buvidal which mean that some patients will respond much better to one specific medication over the other. He noted that they sometimes see those patients who require higher doses do much better with the Sublocade product, and the duration of the action can also be different between the two options. Choice for the patient and the healthcare provider is extremely important and can be the deciding factor that determines successful engagement in long-term treatment or, conversely, a dangerous return to illicit drug use. But he argued that it is not just the simple matter of choice that is the main issue here. If we only have one drug left, and for some entirely unforeseeable reason it cannot be accessed, then that is a massive issue for the entire community. The addiction treatment space is a very delicate ecosystem with an already vulnerable cohort that now seems to have been dealt another very unfair result.

Check our latest news